310 related articles for article (PubMed ID: 32845114)
1. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
2. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
3. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Snape SD; Wigger-Alberti W; Goehring UM
Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
Smith B; Collier MR; Wu JJ
JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
[No Abstract] [Full Text] [Related]
6. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
Lebwohl MG; Hebert AA; Gooderham MJ
JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
[No Abstract] [Full Text] [Related]
7. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
Thurston AW; Osborne DW; Snyder S; Higham RC; Burnett P; Berk DR
Am J Clin Dermatol; 2023 Mar; 24(2):315-324. PubMed ID: 36422852
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
[TBL] [Abstract][Full Text] [Related]
11. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.
Watz H; Bagul N; Rabe KF; Rennard S; Alagappan VK; Román J; Facius A; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2018; 13():813-822. PubMed ID: 29563781
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
Gooderham M; Kircik L; Zirwas M; Lee M; Kempers S; Draelos Z; Ferris L; Jones T; Saint-Cyr Proulx E; Bissonnette R; Bhatia N; Koppel R; Guenthner S; Eads K; Welgus H; Merritt C; Elias M; Navale L; Higham R; Droege M; Berk D
J Drugs Dermatol; 2023 Feb; 22(2):139-147. PubMed ID: 36745371
[TBL] [Abstract][Full Text] [Related]
14. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
15. Topical Roflumilast for Plaque Psoriasis.
O'Toole A; Gooderham M
Skin Therapy Lett; 2023 Sep; 28(5):1-4. PubMed ID: 37734074
[TBL] [Abstract][Full Text] [Related]
16. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants.
Cook-Bolden FE; Hebert AA; Guenthner ST; Kang R; Martin G; Jacobson A
J Drugs Dermatol; 2020 Aug; 19(8):747-754. PubMed ID: 32845589
[TBL] [Abstract][Full Text] [Related]
17. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Eckermann G; Lahu G; Nassr N; Bethke TD
J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
[TBL] [Abstract][Full Text] [Related]
18. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
19. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
